134 related articles for article (PubMed ID: 19635201)
1. [Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Zhao YY; Zhang Y; Zhao HY; Wu JX; Jiang W; Xue C; Zhang L
Ai Zheng; 2009 Jun; 28(6):626-31. PubMed ID: 19635201
[TBL] [Abstract][Full Text] [Related]
2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Huang H; Zhang Y; Zhao HY; Wang ZQ; Xu F; Xu GC; Zhang L; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):148-51. PubMed ID: 19538895
[TBL] [Abstract][Full Text] [Related]
4. [Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Gu AQ; Wang HM; Shi CL; Xiong LW; Gao ZQ; Han BH
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):71-4. PubMed ID: 20211075
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
[TBL] [Abstract][Full Text] [Related]
6. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
[TBL] [Abstract][Full Text] [Related]
8. [Gefitinib in the treatment of advanced non-small cell lung cancer].
Yang L; Liu XY; Fang J; An TT; Wu MN
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Xu JM; Li YM; Liu XQ; Zhang Y; Han Y; Yang WW; Song ST
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):66-9. PubMed ID: 17575699
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Guan ZZ; Zhang L; Li LY; Jiang GL; Liu XY; Chu DT; Zhao HY; Li W
Ai Zheng; 2005 Aug; 24(8):980-4. PubMed ID: 16086877
[TBL] [Abstract][Full Text] [Related]
11. [Gefitinib in the treatment of advanced non-small-cell lung cancer].
Zhang L; Yu SY
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):539-41. PubMed ID: 17147123
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Wen ZS; Chen XQ; Wu HY; Wei WD; Rong TH
Ai Zheng; 2007 Apr; 26(4):415-7. PubMed ID: 17430664
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
[TBL] [Abstract][Full Text] [Related]
14. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Mohamed MK; Ramalingam S; Lin Y; Gooding W; Belani CP
Ann Oncol; 2005 May; 16(5):780-5. PubMed ID: 15728108
[TBL] [Abstract][Full Text] [Related]
15. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
20. [Gefitinib in the treatment of refractory non-small cell lung cancer].
Xu JF; Zhou CC; Li AW
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):938-40. PubMed ID: 18478936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
